Characterizing the Drug Development Pipeline for Precision Medicines

Amitabh Chandra, Craig Garthwaite, Ariel Dora Stern

NBER Working Paper No. 24026
Issued in November 2017, Revised in May 2018

---- Acknowledgments ----

We are grateful to Brian Alexander, Can Huang, Jennifer Kao, Rebecca Sachs, Mark Trusheim, a helpful anonymous reviewer, and participants in workshops for the NBER Project on Economic Dimensions of Personalized and Precision Medicine, the NBER-AIEA Conference, and the Bates White Life Sciences Symposium, for helpful comments. Ben Berger, Holly Breuer, Lila Kelso, Andrew Marder, Caroline Marra, and Alice Ndikumana provided excellent research and programming assistance. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

return to bibliography page